CD123 by IHC

Alphabetical Test listing

CD123 by IHC-12376 - Technical only, 12379 - Technical & interpretation

  
CD123 by IHC
  
12376 - Technical only, 12379 - Technical & interpretation
  
LAB12376
LAB12379
  
IL-3 alpha-chain receptor
  
  • All IHC stains will include a positive control tissue
  
  • CD123 identifies blastic plasmacytoid dendritic cell (BPDC) neoplasms, which tend to involve multiple sites, with predilection for skin (almost 100% of cases), followed by bone marrow (60-90%) and other sites. 10-20% of cases are associated with or develop into AML
  • CD 123 is most useful in an antibody panel designed to detect BPDC neoplasms, which are CD4+, CD56+, CD68+ (50% have cytoplasmic dot staining), and TdT (33% positive). Tumors that share some but not all immunophenotypic features of BPDC are better classified as "acute leukemia of ambiguous lineage"
  
Tissue
  

Submit a formalin-fixed, paraffin embedded tissue block

  

Formalin-fixed, paraffin embedded (FFPE) tissue block

  

FFPE tissue section mounted on a charged, unstained slide

  

Ambient (preferred)

  
  • Unlabeled/mislabeled block
  • Insufficient tissue
  • Slides broken beyond repair
  
AHL - Immunohistochemistry
  
Mo - Fr
  
1 - 2 days
  

Immunohistochemical staining and microscopic examination

  

If requested, an interpretive report will be provided

  

Specifications

  • CD123 antibody reacts with IL-3 receptor alpha chain which is expressed on normal plasmacytoid dendritic cells
  • CD 123 reactivity with does not occur on other hematopoietic progenitor cells, but has not been extensively studied

Staining pattern

  • Membrane -based staining

References

  1. WHO (2008) classification of tumors of hematopoietic and lymphoid tissues, p145-147.
  
88342 - 1st stain
88341 - each additional stain
  
06/16/2017
  
10/17/2018
  
10/02/2020